Epirubicin + lipiodol
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Hepatocellular
Conditions
Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
Trial Timeline
Dec 1, 2015 → Dec 1, 2019
NCT ID
NCT02631499About Epirubicin + lipiodol
Epirubicin + lipiodol is a approved stage product being developed by Johnson & Johnson for Carcinoma, Hepatocellular. The current trial status is unknown. This product is registered under clinical trial identifier NCT02631499. Target conditions include Carcinoma, Hepatocellular, Neoplastic Cells, Circulating.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Hepatocellular were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02631499 | Approved | UNKNOWN |
Competing Products
20 competing products in Carcinoma, Hepatocellular